Prostate cancer and markers of bone metabolism: Diagnostic, prognostic, and therapeutic implications

World Journal of Urology

Volumn 25, Issue 4, 2007, Pages 393-399

  Nelson, Eric C ^a   Evans, Christopher P ^a   Pan, Chong Xian ^b   Lara Jr , Primo N ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Androgen independent prostate cancer; Bone markers; Bone metastases; Osteoprotegerin; Prostate cancer

Indexed keywords

TUMOR MARKER;

BONE TUMOR; DIFFERENTIAL DIAGNOSIS; HUMAN; MALE; METABOLISM; METASTASIS; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR; REVIEW;

BONE NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; HUMANS; MALE; PROGNOSIS; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 34548175778     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-007-0186-3     Document Type: Review

References (38)

1. Michaelson MD, Smith MR (2005) Bisphosphonates for treatment and prevention of bone metastases. J Clin Oncol 23(32):8219-8224
2. Smith MR (2006) Markers of bone metabolism in prostate cancer. Cancer Treat Rev 1 (32 Suppl):23-26
3. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352(2):154-164
4. Hussain SA, Weston R, Stephenson RN, George E, Parr NJ (2003) Immediate dual energy X-ray absorptiometry reveals a high incidence of osteoporosis in patients with advanced prostate cancer before hormonal manipulation. BJU Int 92(7):690-694
5. Berruti A, Dogliotti L, Bitossi R, Fasolis G, Gorzegno G, Bellina M et al (2000) Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: Predictive role of bone resorption and formation markers evaluated at baseline. J Urol 164(4):1248-1253
6. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L et al (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96(11):879-882
7. Fontana A, Delmas PD (2000) Markers of bone turnover in bone metastases. Cancer 88(12 Suppl):2952-2960
8. Suvanto-Luukkonen E, Risteli L, Sundstrom H, Penttinen J, Kauppila A, Risteli J (1997) Comparison of three serum assays for bone collagen formation during postmenopausal estrogen-progestin therapy. Clin Chim Acta 266(2):105-116
9. Arai Y, Takeuchi H, Oishi K, Yoshida O (1992) Osteocalcin: Is it a useful marker of bone metastasis and response to treatment in advanced prostate cancer? Prostate 20(3):169-177
10. Hanson DA, Eyre DR (1996) Molecular site specificity of pyridinoline and pyrrole cross-links in type I collagen of human bone. J Biol Chem 271(43):26508-26516
11. Demers LM, Costa L, Lipton A (2000) Biochemical markers and skeletal metastases. Cancer 88(12 Suppl):2919-2926
12. Hanson DA, Weis MA, Bollen AM, Maslan SL, Singer FR, Eyre DR (1992) A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 7(11):1251-1258
13. Tamada T, Sone T, Tomomitsu T, Jo Y, Tanaka H, Fukunaga M (2001) Biochemical markers for the detection of bone metastasis in patients with prostate cancer: Diagnostic efficacy and the effect of hormonal therapy. J Bone Miner Metab 19(1):45-51
14. Hofbauer LC, Neubauer A, Heufelder AE (2001) Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: Potential implications for the pathogenesis and treatment of malignant bone diseases. Cancer 92(3):460-470
15. Koga H, Naito S, Koto S, Sakamoto N, Nakashima M, Yamasaki T et al (1999) Use of bone turnover marker, pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (ICTP), in the assessment and monitoring of bone metastasis in prostate cancer. Prostate 39(1):1-7
16. Koizumi M, Yonese J, Fukui I, Ogata E (2001) The serum level of the amino-terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone. BJU Int 87(4):348-351
17. de la Piedra C, Castro-Errecaborde NA, Traba ML, Mendez-Davila C, Garcia-Moreno C, Rodriguez de Acuna L et al (2003) Bone remodeling markers in the detection of bone metastases in prostate cancer. Clin Chim Acta 331(1-2):45-53
18. Jung K, Lein M, Stephan C, Von Hosslin K, Semjonow A, Sinha P et al (2004) Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: Diagnostic and prognostic implications. Int J Cancer 111(5):783-791
19. Takeuchi S, Arai K, Saitoh H, Yoshida K, Miura M (1996) Urinary pyridinoline and deoxypyridinoline as potential markers of bone metastasis in patients with prostate cancer. J Urol 156(5):1691-1695
20. Petrylak DP, Scher HI, Li Z, Myers CE, Geller NL (1992) Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone-refractory prostatic cancer treated with single-agent chemotherapy. Cancer 70(12):2870-2878
21. Kelly WK, Scher HI, Mazumdar M, Vlamis V, Schwartz M, Fossa SD (1993) Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 11(4):607-615
22. Smaletz O, Scher HI, Small EJ, Verbel DA, McMillan A, Regan K et al (2002) Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 20(19):3972-3982
23. Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA et al (2003) Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 21(7):1232-1237
24. Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M et al (2005) Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97(1):59-69
25. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L et al (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94(19):1458-1468
26. Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M et al (2003) Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial - the Zoledronic acid lung cancer and other solid tumors study group. J Clin Oncol 21(16):3150-3157
27. Cook RJ, Coleman R, Brown J, Lipton A, Major P, Hei YJ et al (2006) Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res 12(11 Pt 1):3361-3367
28. Lara PN Jr, Stadler WM, Longmate J, Quinn DI, Wexler J, Van Loan M et al (2006) A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases. Clin Cancer Res 12(5):1556-1563
29. Lara PN, Longmate J, Stadler W, van Loan M, Wexler J, Quinn DI et al (2005) Markers of bone metabolism predict survival in hormone refractory prostate cancer (HRPC): Results from a randomized California Cancer Consortium and Univ of Chicago trial. J Clin Oncol 23S(16S) Abst 4569
30. Nelson JB (2005) Endothelin receptor antagonists. World J Urol 23(1):19-27
31. Yoshida K, Sumi S, Arai K, Koga F, Umeda H, Hosoya Y et al (1997) Serum concentration of type I collagen metabolites as a quantitative marker of bone metastases in patients with prostate carcinoma. Cancer 80(9):1760-1767
32. Koizumi M, Yonese J, Fukui I, Ogata E (2002) Metabolic gaps in bone formation may be a novel marker to monitor the osseous metastasis of prostate cancer. J Urol 167(4):1863-1866
33. Holen I, Shipman CM (2006) Role of osteoprotegerin (OPG) in cancer. Clin Sci (Lond) 110(3):279-291
34. Eaton CL, Wells JM, Holen I, Croucher PI, Hamdy FC (2004) Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer. Prostate 59(3):304-310
35. Cross SS, Yang Z, Brown NJ, Balasubramanian SP, Evans CA, Woodward JK et al (2006) Osteoprotegerin (OPG) - a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis? Int J Cancer 118(8):1901-1908
36. Berruti A, Dogliotti L, Gorzegno G, Torta M, Tampellini M, Tucci M et al (1999) Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases. Clin Chem 45(8 Pt 1):1240-1247
37. Berruti A, Tucci M, Mosca A, Tarabuzzi R, Gorzegno G, Terrone C et al (2005) Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease. Br J Cancer 93(6):633-638
38. Coleman RE, Major P, Lipton A, Brown JE, Lee KA, Smith M et al (2005) Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23(22):4925-4935